About HTCR-Services

Human Tissue and Cell Research-Services GmbH (HTCR-Services) is a wholly-owned subsidiary of HTCR-Foundation to reflect our commitment and vision of making high quality human biospecimens available to the medical research community.

Founded in 2002 as a spin-off from the University of Regensburg, HTCR-Services offers human tissue-based products and services for medical research and drug development applications.

With access to a network of leading hospitals and surgeons, HTCR-Services provides a broad range of diseased / normal tissues and matching biospecimens (e.g. blood samples, PBMCs) accelerating the discovery of new drugs and treatment options.

Confidence in Translational Medicine

Professional network of hospitals and medical KOLs

Human biospecimens and primary cells are collected or isolated from remnant surgical tissues of consented patients within our hospital network. In order to assure the proper collection, processing and use of human biospecimens, HTCR-Services delivers the material  and associated clinical under the strict ethical and legal framework of the Human Tissue and Cell Research Foundation (HTCR).


    Our collaborating BioBanks maintain human tissue repositories of more than 40,000 samples from 4,000 donors. Tissue samples from over 600 consented donors are collected annually, mostly with oncological Read more

    We collect human tissues and/or the biological fluids from the same donor to meet the research requirements of our customers. The samples and/or cells can be provided freshly-collected or in multiple preserved formats according customer specifications.... read more
  • Our Portfolio

    Download and overview:  Portfolio

    Moving drugs from bench to bedside involves extensive characterization for safety and efficacy in pre-clinical studies using human-based cellular systems and animal models. However inadequate representation of the human tissue environment in pre-clinical models results in poorly validated therapeutic targets and inaccurate predictions of the drug candidate’s effects on humans. Resulting typically in high failure rate in clinical trials... read more